Referred to the House Committee on Energy and Commerce.
This bill, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 (H.R. 5160), reauthorizes and extends the C.W. Bill Young Cell Transplantation Program and related cord blood inventory activities. It amends 42 U.S.C. 274m to continue appropriations at $31,009,000 and to authorize $33,009,000 annually for fiscal years 2027 through 2031.
Degree of support for continued federal spending: liberals most supportive, conservatives more skeptical.
Relative to its intended legislative type, this bill is a narrowly focused reauthorization/appropriation-authority amendment that clearly identifies statutory targets and funding levels but adds little procedural, reporting, or contingency detail beyond the amendments themselves.
This bill, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 (H.R. 5160), reauthorizes and extends the C.W. Bill Young Cell Transplantation Program and related cord blood inventory activities.
It amends 42 U.S.C. 274m to continue appropriations at $31,009,000 and to authorize $33,009,000 annually for fiscal years 2027 through 2031.
It also amends 42 U.S.C. 274k to extend the statutory timeframe for the cord blood inventory program from 2026 to 2031.
Judged only by its text, the bill is a routine, narrow reauthorization with a small fiscal increase and no obvious ideological flashpoints — characteristics that historically increase the odds of enactment. The main limiting factors are that authorization does not guarantee appropriation, potential procedural obstacles in either chamber, and the possibility the measure could be delayed or amended within larger legislative negotiations.
Relative to its intended legislative type, this bill is a narrowly focused reauthorization/appropriation-authority amendment that clearly identifies statutory targets and funding levels but adds little procedural, reporting, or contingency detail beyond the amendments themselves.
Degree of support for continued federal spending: liberals most supportive, conservatives more skeptical.
These are examples from the analysis, not a ranked list of the most-affected groups.
Degree of support for continued federal spending: liberals most supportive, conservatives more skeptical.
A mainstream progressive would likely view this bill favorably because it sustains federal support for a public cell transplantation and cord blood inventory program that can expand access to lifesaving transplants and support research.
They would see continuation of funding as aligned with priorities for public health infrastructure, equitable donor registries, and translational biomedical research.
However, they may consider the authorized amounts modest and want stronger language on equity, outreach to underrepresented donors, data transparency, and protection of research freedoms.
A pragmatic moderate would generally approve of reauthorizing a targeted public health program with modest, specified funding increases while asking for accountability.
They would view this as a narrow, incremental extension of an existing program rather than a sweeping policy change, but would want evidence that the additional funds produce measurable improvements.
Their default position would be conditional support pending oversight and cost-effectiveness assurances.
A mainstream conservative would approach the bill with caution: supportive of effective medical and therapeutic programs in principle but concerned about adding or continuing federal expenditures without stronger evidence of efficiency.
They may welcome the focus on therapeutic transplant capacity and cord blood inventory while objecting to the federal role if it appears duplicative of state or private efforts.
Some conservatives might also raise concerns about any indirect support for controversial stem cell research, although this bill focuses on cord blood/ transplantation rather than embryonic stem cell policy.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Judged only by its text, the bill is a routine, narrow reauthorization with a small fiscal increase and no obvious ideological flashpoints — characteristics that historically increase the odds of enactment. The main limiting factors are that authorization does not guarantee appropriation, potential procedural obstacles in either chamber, and the possibility the measure could be delayed or amended within larger legislative negotiations.
The bill has not accumulated any surfaced votes yet.
Degree of support for continued federal spending: liberals most supportive, conservatives more skeptical.
Judged only by its text, the bill is a routine, narrow reauthorization with a small fiscal increase and no obvious ideological flashpoints…
Relative to its intended legislative type, this bill is a narrowly focused reauthorization/appropriation-authority amendment that clearly identifies statutory targets and funding levels but adds little procedural, repor…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.